Syreon Research Institute’s Post

If you're interested in improving patient access to precision oncology, check out this paper exploring a life-cycle approach for these therapies. Also, my first peer-reviewed journal article 📚 https://lnkd.in/dxWEb29Q

Our work with healthcare systems is key to advancing research, encouraging new discoveries, and meeting growing clinical demands.    Today, we are proud to announce our efforts with Peter MacCallum Cancer Centre to explore the possibilities of a new, innovative long axial field-of-view PET/CT technology* designed to provide exceptionally high image quality at ultra-low dose to help enable the investigation of new clinical pathways in oncology.   GE HealthCare is proud to drive innovation that helps support and advance healthcare research and investigation. I am excited to see how this evolving technology could help advance the capabilities of today’s molecular imaging technologies and help enhance personalized treatment approaches.   https://lnkd.in/gh6vvcUR   #GEHealthCare #FutureofHealthcare #PeterMacCallum #PrecisionCare #Innovation #Theranostics #Oncology   *Technology in development. Not for sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability. Michael Hofman Stephen Stuckey Elie Chaillot Roland Rott Ben Newton Christopher Porter Peter Peralta Leon Berkovich Mark Stoesz Jean-Philippe Bousquel

🔬Precision Oncology: Overcoming Access Challenges for Innovative Therapies Precision oncology uses molecular insights to tailor therapies for individual patients. As scientific advancements unlock new possibilities, traditional pathways face problems that delay patient access to treatments. Key Points: 🔹Scientific breakthroughs offer promising avenues for cancer treatment. However, existing frameworks and approval processes often hinder patient access. 🔹Life-Cycle Approach: Adopting a comprehensive life-cycle assessment for precision oncology and tumour-agnostic drugs is paramount to unlocking their full potential. 🔹Shared Responsibility: Addressing access challenges requires collective action from all stakeholders, recognising the mutual benefits of collaborative solutions. Supporting a life-cycle assessment paradigm for precision oncology starts a new era of patient-centric care. By expanding access to comprehensive testing, encouraging collaborative dialogue, and adopting innovative payment models, we can navigate the complexities of modern healthcare systems and ensure every patient receives the care they deserve. Find out more from Priscila Radu, Gayathri Kumar, Amanda Cole, Aikaterini Fameli, PhD, MBA, Mark Guthrie, Lieven Annemans, Jan Geissler, Italiano Antoine, Brian O’Rourke, Entela Xoxi and Prof. Lotte Steuten, PhD here: https://lnkd.in/dxWEb29Q #innovativetherapies #oncology #patientaccess

Today, we spotlight new research powered by the 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗠𝗜𝗗𝗗 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗼𝗿—an innovative tool improving how treatment efficacy is assessed in early oncology trials. Traditionally, decisions hinge on long-term overall survival data, delaying critical progress. The MIDD Simulator disrupts this norm by leveraging early indicators like tumor growth inhibition, delivering actionable insights faster and empowering researchers to make informed decisions sooner. 𝗞𝗲𝘆 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝘀: 🔹 PK Module: Simulates drug exposure 🔹 TGI Module: Tracks tumor shrinkage and regrowth 🔹 OS Module: Forecasts overall survival By integrating real-time data, this tool empowers researchers with faster, more informed decision-making, accelerating the path to delivering life-saving therapies to patients. 🧠 Contributors: Mourad HAMIMED | Mathilde Marchand | Antonio Gonçalves | Vincent Duval | Mirjam Trame | Samer Mouksassi, Pharm.D., PhD, FCP 💡 Learn More: View our research poster featured at ACoP15: https://lnkd.in/dyQN6ctX 📅 Let’s Connect: Are you looking for guidance with oncology forecasting? Book a complimentary 15-minute consultation: https://lnkd.in/di3wBFpg #MIDD #Oncology #CancerTreatment #DrugDevelopment #PrecisionMedicine #ACoP

Navigating Early-Phase Trials in Oncology with Bayesian and Frequentist Designs : This on-demand webinar will equip you with the knowledge to navigate the complexities of early-phase trials. ✔️Gain insights into the key features of bayesian and frequentist designs ✔️Discover how targeted agents and immunotherapy are being investigated through innovative trial designs ✔️Delve into critical statistical caveats such as the early incorporation of randomization, the challenges of sample-size calculation, and the strategic use of biomarkers for more efficient trial outcomes.  https://lnkd.in/e7dJ3DR3  #trialdesign #bayeasiandesign #frequentistdesign #Phase1trials #immunotherapy #clinicalresearch

𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐚𝐧𝐝 𝐅𝐮𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬 🌐𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑷𝑫𝑭 𝑩𝒓𝒐𝒄𝒉𝒖𝒓𝒆: bit.ly/3WOVxRK The report "#cancerdiagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) - Global Forecasts to 2026" 𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟐𝟔.𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟔 𝐟𝐫𝐨𝐦 𝐔𝐒𝐃 𝟏𝟕.𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟏, 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟏.𝟓%. The growth in this market is attributed to the increasing incidence of cancer and increasing number of private diagnostic laboratories. Danaher Corporation, Becton, Dickinson and Company, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, QIAGEN, FUJIFILM Corporation, Thermo Fisher Scientific, etc. #cancerdiagnostics #cancerdetection #oncologytesting #precisionmedicine #earlydetection #tumordiagnosis #medicalimaging #biomarkertesting #liquidbiopsy #personalizedmedicine #genetictesting #cancerscreening #pathologyservices #moleculardiagnostics 

📰 Press Release: Farcast Biosciences to Deliver Keynote Address at the Immuno-Oncology Xchange in San Francisco 2024! 🗞️ Farcast Biosciences the developer of the cutting-edge TruTumor platform, will present the Keynote Opening Address at hubXchange’s West Coast Immuno-Oncology Xchange on September 24, 2024. This event is a key gathering for thought leaders and experts in Immuno-Oncology, providing an opportunity to collaborate on overcoming the biggest challenges in drug research, development, and patient care. The Keynote, delivered by Christopher Davitt, PhD, will focus on "Unlocking Tumor-Immune Dynamics: How TruTumor Histoculture Reveals Head and Neck Cancer Responses to Checkpoint Therapy", presenting outcomes from a recent study on tumor microenvironment responses to anti-PD1 therapy in head and neck cancer patients. 💡 Don’t miss this opportunity to explore ground-breaking insights and network with top professionals in the field! 🔗 Learn more and register for free!: https://lnkd.in/efi7giAi Read the full article here! https://lnkd.in/eCMzBagk #ImmunoOncology #TruTumor #CancerResearch #CheckPointTherapy #DrugDevelopment #hubXchange #FarcastBiosciences #hubxchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

BREAST CANCER PIPELINE 2024 Breast cancer remains a formidable challenge due to late-stage diagnosis, which limits treatment options and efficacy. Treatment resistance, where cancer cells adapt and evade therapies, poses a significant hurdle. The rising global incidence of breast cancer, driven by lifestyle changes and an aging population, is a key market driver. Technological advancements in diagnostics and treatment, such as molecular imaging, targeted therapies, and precision medicine, are boosting demand and improving patient outcomes. Increased awareness and participation in screening programs further expand the market. However, the high cost of treatment remains a significant barrier, limiting access in certain regions. Source: DelveInsight Business Research LLP #BreastCancerAwareness #ClinicalTrials #Innovation #Healthcare #Research Genentech Takeda AbbVie ALX Oncology Hengrui Pharma Co.,Ltd

🗣 EXINI is proud to join the Thera4Care project! 🚀 We’re part of a European initiative that’s set to revolutionize the use of theranostics and to broaden patient access in Europe – a groundbreaking method that combines diagnostics with targeted therapies for personalized treatment. Our AI expertise will enhance imaging technologies and help tailor cancer treatment protocols,, driving better outcomes for patients and advancing precision oncology. Key goals of Thera4Care: 🔬 Strengthen the manufacturing and supply chain of radiotheranostics 🧪 Develop advanced cancer models to test these therapies in the lab. 📊 Create frameworks for phase 1 clinical trials 🤖 Enhance clinical outcomes through AI-based imaging and personalized dosing protocols. Learn more about our role in this innovative project on our website (see link in the comments) #Thera4Care #AIinHealthcare #EXINI

✨ What does it mean to work with Median Technologies? ✨ At Median, we deliver imaging excellence for oncology clinical trials. With 100% focus on oncology, we bring unparalleled expertise in cancer indications, therapies, and imaging criteria, making us a trusted partner in managing imaging for Phase I-III studies. 🔍 Comprehensive and Tailored Services From end-to-end central imaging solutions to collect-and-hold projects, we go beyond expectations to deliver precisely what your study needs—even offering specialized radiopharmaceutical services for advanced therapeutic strategies. 🌍 Proven Track Record, Global Reach Having supported over 270+ oncology clinical trials worldwide, we combine scientific rigor with operational excellence to ensure your trials run smoothly, every time. 💡 Innovation at the Forefront Within Imaging Lab, we leverage AI, Machine Learning, and radiomics to uncover predictive biomarkers, enhance trial inclusivity, and drive cancer research forward. Learn more about our services here: https://lnkd.in/dgNWW3gj   #Oncology #ClinicalTrials #Radiopharmaceuticals #Innovation #ImagingExcellence